IL316898A - Amido heteroaromatic compounds useful in the treatment of liver diseases - Google Patents
Amido heteroaromatic compounds useful in the treatment of liver diseasesInfo
- Publication number
- IL316898A IL316898A IL316898A IL31689824A IL316898A IL 316898 A IL316898 A IL 316898A IL 316898 A IL316898 A IL 316898A IL 31689824 A IL31689824 A IL 31689824A IL 316898 A IL316898 A IL 316898A
- Authority
- IL
- Israel
- Prior art keywords
- amido
- treatment
- compounds useful
- liver diseases
- heteroaromatic compounds
- Prior art date
Links
- -1 Amido heteroaromatic compounds Chemical class 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263364976P | 2022-05-19 | 2022-05-19 | |
| US202263367843P | 2022-07-07 | 2022-07-07 | |
| US202263383982P | 2022-11-16 | 2022-11-16 | |
| PCT/EP2023/063424 WO2023222850A1 (en) | 2022-05-19 | 2023-05-18 | Amido heteroaromatic compounds useful in the treatment of liver diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316898A true IL316898A (en) | 2025-01-01 |
Family
ID=86646721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316898A IL316898A (en) | 2022-05-19 | 2023-05-18 | Amido heteroaromatic compounds useful in the treatment of liver diseases |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20230373983A1 (en) |
| EP (2) | EP4635494A3 (en) |
| JP (2) | JP7770594B2 (en) |
| KR (1) | KR102963549B1 (en) |
| CN (1) | CN119173506A (en) |
| AU (1) | AU2023274003B2 (en) |
| CA (1) | CA3256765A1 (en) |
| CL (1) | CL2024003495A1 (en) |
| CO (1) | CO2024017138A2 (en) |
| CR (1) | CR20240536A (en) |
| DK (1) | DK4514782T3 (en) |
| DO (1) | DOP2024000239A (en) |
| ES (1) | ES3057934T3 (en) |
| FI (1) | FI4514782T3 (en) |
| HR (1) | HRP20251564T1 (en) |
| IL (1) | IL316898A (en) |
| LT (1) | LT4514782T (en) |
| MA (1) | MA70477B1 (en) |
| MX (1) | MX2024014315A (en) |
| PE (1) | PE20250791A1 (en) |
| PL (1) | PL4514782T3 (en) |
| PT (1) | PT4514782T (en) |
| RS (1) | RS67515B1 (en) |
| SI (1) | SI4514782T1 (en) |
| SM (1) | SMT202500465T1 (en) |
| TW (1) | TWI919070B (en) |
| UY (1) | UY40282A (en) |
| WO (1) | WO2023222850A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025104697A1 (en) | 2023-11-16 | 2025-05-22 | Astrazeneca Ab | Heteroaromatic 17beta hydroxy steroid dehydrogenase 13 inhibitors |
| WO2025104564A1 (en) * | 2023-11-16 | 2025-05-22 | Astrazeneca Ab | Crystalline form of an amido heteroaromatic compound |
| KR20260113258A (en) * | 2023-11-16 | 2026-07-21 | 아스트라제네카 아베 | uracil compounds |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1030415A (en) | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | Saturated heterocyclic carbonamide derivative and its preparation method |
| JPH0696532B2 (en) | 1988-08-11 | 1994-11-30 | 山之内製薬株式会社 | Platelet activating factor antagonist |
| CN1691944A (en) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| WO2004014881A2 (en) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| PE20060285A1 (en) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS |
| EA200901573A1 (en) | 2007-05-22 | 2010-04-30 | Ачиллион Фармасьютикалз, Инк. | Heteroaryl Thiazole Substituents |
| EP2002834A1 (en) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl and hetaryl amides as modulators of EP2 receptors |
| BRPI0907844B8 (en) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compounds and method for modulating an androgen receptor, preparation processes and pharmaceutical composition thereof and their uses |
| WO2009126782A1 (en) | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
| US20090318429A1 (en) | 2008-04-28 | 2009-12-24 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
| US20100144733A1 (en) | 2008-04-28 | 2010-06-10 | Institute For Oneworld Health | Compounds, compositions and methods comprising heteroaromatic derivatives |
| EP2350067A2 (en) | 2008-10-16 | 2011-08-03 | Schering Corporation | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| EP2550266B1 (en) | 2010-03-24 | 2018-05-09 | Amitech Therapeutics Solutions, Inc. | Heterocyclic compounds useful for kinase inhibition |
| KR101559883B1 (en) | 2013-10-30 | 2015-10-13 | 동국대학교 산학협력단 | 2-Amino-substituted oxadiazole derivatives and pharmaceutical composition comprising the same |
| WO2015090579A1 (en) | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides iv |
| US20170290337A1 (en) | 2014-09-24 | 2017-10-12 | Syngenta Participations Ag | Herbicidal Pyridino-/Pyrimidino-Thiazoles |
| JP2017538676A (en) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | Small molecule inhibitors of mitochondrial permeability transition pore (mtPTP) |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| WO2018112077A1 (en) | 2016-12-13 | 2018-06-21 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| KR102736865B1 (en) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | Compounds that interact with the Ras superfamily for the treatment of cancer, inflammatory diseases, neurodevelopmental diseases and fibrotic diseases |
| WO2019036562A1 (en) * | 2017-08-18 | 2019-02-21 | Saint Louis University | Err inverse agonists |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| CN112566636A (en) | 2018-04-25 | 2021-03-26 | 优曼尼蒂治疗公司 | Compound and use thereof |
| JP2021536458A (en) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | Aryl Hydrocarbon Receptor Antagonists and Usage |
| EP3919489A4 (en) | 2019-01-31 | 2022-10-12 | The National Institutes of Pharmaceutical R&D Co., Ltd | Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof |
| MA56457A (en) | 2019-07-02 | 2022-05-11 | Regeneron Pharma | HSD17B13 MODULATORS AND METHODS OF USE THEREOF |
| WO2021050555A1 (en) | 2019-09-10 | 2021-03-18 | X-Chem, Inc. | Compositions and uses thereof |
| WO2021138450A1 (en) | 2019-12-30 | 2021-07-08 | Buto Corporation | Novel small molecule shc blockers for treating liver disease and metabolic disease |
| WO2021211974A1 (en) | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Hsd17b13 inhibitors and uses thereof |
| CA3179059A1 (en) * | 2020-06-09 | 2021-12-16 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| JP2023537271A (en) | 2020-07-24 | 2023-08-31 | イニファーム,インク. | Thiophene HSD17B13 inhibitors and uses thereof |
| CN116194440A (en) | 2020-07-24 | 2023-05-30 | 伊尼制药公司 | Quinazolinone HSD17B13 inhibitors and uses thereof |
| WO2022040324A1 (en) | 2020-08-18 | 2022-02-24 | Metrea Biosciences, Inc. | COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13 |
| EP4221701A1 (en) | 2020-09-30 | 2023-08-09 | FL2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| MX2023003677A (en) | 2020-09-30 | 2023-06-22 | Fl2022 001 Inc | Hsd17b13 inhibitors and uses thereof. |
| US20240083861A1 (en) | 2020-09-30 | 2024-03-14 | Fl2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| CN116670118B (en) | 2020-11-13 | 2026-02-06 | 伊尼制药公司 | Dichlorophenol HSD17B13 inhibitor and application thereof |
| WO2022149617A1 (en) | 2021-01-06 | 2022-07-14 | 中外製薬株式会社 | Compound library |
| TWI884348B (en) | 2021-01-06 | 2025-05-21 | 日商中外製藥股份有限公司 | Alkylation method of acidic functional groups |
| US12617772B2 (en) | 2021-04-05 | 2026-05-05 | Inipharm, Inc. | Hydroxypyridine HSD17B13 inhibitors and uses thereof |
| EP4319872A4 (en) | 2021-04-05 | 2025-03-12 | Inipharm, Inc. | THIAZOLE/ISOTHIAZOLE TYPE HSD17B13 INHIBITORS AND USES THEREOF |
| WO2022226349A1 (en) | 2021-04-22 | 2022-10-27 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| KR20240016327A (en) | 2021-06-01 | 2024-02-06 | 신젠타 크롭 프로텍션 아게 | Microbicidal tetrahydroisoquinoline derivatives |
| EP4469451A4 (en) | 2022-01-26 | 2025-12-24 | Inipharm Inc | 2-SUBSTITUTED THIAZOLE HSD17B13 HIBITORS AND USES THEREBY |
-
2023
- 2023-05-18 HR HRP20251564TT patent/HRP20251564T1/en unknown
- 2023-05-18 SI SI202330062T patent/SI4514782T1/en unknown
- 2023-05-18 JP JP2024568294A patent/JP7770594B2/en active Active
- 2023-05-18 RS RS20251263A patent/RS67515B1/en unknown
- 2023-05-18 IL IL316898A patent/IL316898A/en unknown
- 2023-05-18 PT PT237278585T patent/PT4514782T/en unknown
- 2023-05-18 US US18/319,560 patent/US20230373983A1/en not_active Abandoned
- 2023-05-18 CA CA3256765A patent/CA3256765A1/en active Pending
- 2023-05-18 ES ES23727858T patent/ES3057934T3/en active Active
- 2023-05-18 EP EP25193254.7A patent/EP4635494A3/en active Pending
- 2023-05-18 KR KR1020247041264A patent/KR102963549B1/en active Active
- 2023-05-18 PL PL23727858.5T patent/PL4514782T3/en unknown
- 2023-05-18 PE PE2024002618A patent/PE20250791A1/en unknown
- 2023-05-18 WO PCT/EP2023/063424 patent/WO2023222850A1/en not_active Ceased
- 2023-05-18 CN CN202380039751.1A patent/CN119173506A/en active Pending
- 2023-05-18 LT LTEPPCT/EP2023/063424T patent/LT4514782T/en unknown
- 2023-05-18 SM SM20250465T patent/SMT202500465T1/en unknown
- 2023-05-18 EP EP23727858.5A patent/EP4514782B1/en active Active
- 2023-05-18 DK DK23727858.5T patent/DK4514782T3/en active
- 2023-05-18 FI FIEP23727858.5T patent/FI4514782T3/en active
- 2023-05-18 AU AU2023274003A patent/AU2023274003B2/en active Active
- 2023-05-18 MA MA70477A patent/MA70477B1/en unknown
- 2023-05-18 CR CR20240536A patent/CR20240536A/en unknown
- 2023-05-19 TW TW112118619A patent/TWI919070B/en active
- 2023-05-19 UY UY0001040282A patent/UY40282A/en unknown
-
2024
- 2024-09-13 US US18/884,381 patent/US12291524B2/en active Active
- 2024-11-15 CL CL2024003495A patent/CL2024003495A1/en unknown
- 2024-11-15 DO DO2024000239A patent/DOP2024000239A/en unknown
- 2024-11-19 MX MX2024014315A patent/MX2024014315A/en unknown
- 2024-12-13 CO CONC2024/0017138A patent/CO2024017138A2/en unknown
-
2025
- 2025-04-15 US US19/179,902 patent/US20260159508A1/en active Pending
- 2025-11-04 JP JP2025185422A patent/JP2026021479A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI4514782T1 (en) | Amido heteroaromatic compounds useful in the treatment of liver diseases | |
| ZA202110597B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL284371A (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL285708A (en) | Imidazopyridinyl compounds and their uses in the treatment of neurodegenerative diseases | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| ZA202007834B (en) | Compositions comprising amino acids for use in the prevention and treatment of liver diseases | |
| IL290722A (en) | Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders | |
| EP3316874A4 (en) | TOPICAL AND INJECTABLE REYQUIMOD COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC SKIN DISEASES | |
| IL288924A (en) | Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer | |
| SG11202111739VA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases | |
| EP3755334A4 (en) | Treatment of liver diseases | |
| IL285751A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| PL3937948T3 (en) | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | |
| IL304606A (en) | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders | |
| GB2609003B (en) | Compounds and pharmaceutical compositions for the treatment of metabolic disorders | |
| GB202012482D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB201907547D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B | |
| GB2609793B (en) | Benzimidazole compound for the treatment of metabolic disorders and liver diseases | |
| GB201911821D0 (en) | Compounds for use in the treatment of liver disease | |
| HK40074734A (en) | Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders | |
| HK40040026A (en) | Heterocyclic compounds useful in the treatment of disease | |
| HK40104579A (en) | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders | |
| HK40096701A (en) | Novel compounds for use in the treatment of diseases associated with angiotensin ii | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases |